Edition:
United Kingdom

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

49.90SEK
15 Dec 2017
Change (% chg)

-0.10kr (-0.20%)
Prev Close
50.00kr
Open
50.25kr
Day's High
50.75kr
Day's Low
49.70kr
Volume
56,345
Avg. Vol
65,592
52-wk High
102.00kr
52-wk Low
47.20kr

Chart for

About

Medivir AB is a Sweden-based pharmaceutical company engaged in the research, development and sale of drugs against widespread diseases, with protease and polymerase as its target enzymes. The Company’s research focuses on developing small molecule pharmaceuticals, primarily against infectious diseases caused by viruses. The... (more)

Overall

Beta: 1.15
Market Cap(Mil.): kr1,394.06
Shares Outstanding(Mil.): 19.84
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Medivir announces new cancer project

* Medivir announces new cancer project, Leukotide, derived from its in-house nucleotide platform

08 Nov 2017

BRIEF-Medivir Q3 EBITDA loss widens

* Says ‍net turnover for continuing operations totalled SEK 5.1 million (25.7 m), SEK 5.1 million (13.5 m) of which comprised Q3's royalties​

26 Oct 2017

BRIEF-Medivir receives FDA fast track designation for MIV-711 for treatment of OA

* Medivir receives FDA fast track designation for MIV-711 for the treatment of OA Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

24 Oct 2017

BRIEF-Medivir says positive top line data from 6-month initial phase IIa study of MIV-711

* Announces positive top line data from MIV-711-201, 6-month initial phase IIa study of MIV-711 in moderate knee osteoarthritis patients Source text for Eikon: Further company coverage:

25 Sep 2017

BRIEF-Medivir: Janssen discontinues development of JNJ-4178 for hepatitis C

* Medivir announces Janssen to discontinue development of JNJ-4178 for hepatitis C

11 Sep 2017

BRIEF-Medivir initiates clinical study of birinapant in combination with keytruda in patients with treatment-refractory solid tumours

* Medivir initiates clinical study of birinapant in combination with keytruda® (pembrolizumab) in patients with treatment-refractory solid tumours Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

18 Aug 2017

BRIEF-Medivir Q2 EBITDA loss widens

* Says net turnover for continuing operations totalled SEK 9.5 million (36.9 m), SEK 7.7 million (24.2 m) of which comprised Q2's royalties for simeprevir

25 Jul 2017

BRIEF-Stendorren Fastigheter extends strategic lease with Medivir

* NEW LEASE AGREEMENT RUNS FOR 10 YEARS FROM 2019 WITH ANNUAL RENTAL VALUE AT ABOUT SEK 5.65 MILLION

29 Jun 2017

Earnings vs. Estimates